Ali H. Alassiri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ali H. Alassiri has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
- Ali Alkhaibary
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
5 shared publications - Fahd AlSufiani
King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
4 shared publications - Ahmed Alkhani
Division of Neurosurgery, Department of Surgery, King Abdulaziz Medical City, Ministry of National Guard - Health Affairs, Riyadh, Saudi Arabia
3 shared publications - Ahmed Aloraidi
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
3 shared publications - Ahoud Alharbi
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
3 shared publications - Sami Khairy
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
3 shared publications
Latest Publications
- Open Access
- 9 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7139
Saudi Patient-Derived Brain and Intracranial Explanted Tumor Cells: Isolation, Growth, and Anticancer Drug Screening
Brain cancer is a highly aggressive disease with limited treatment options, highlighting the need for reliable preclinical models for drug discovery. This study aimed to isolate and characterize Saudi patient-derived primary brain cancer cells and assess the anticancer activity of novel compounds developed in-house. Sixteen tumor samples from Saudi patients were processed to establish primary brain cancer cultures and One Normal Tissue (Control). The cells were successfully isolated and maintained under optimized conditions, with their morphology and growth characteristics monitored. Molecular analysis confirmed the expression of key tumor and neural markers. The anticancer activity of selected compounds, KCO69, KCO70, and KCO129, was tested at various concentrations using the MTT and CellTiter-Glo Luminescent Cell Viability Assay. All compounds caused a concentration-dependent reduction in cell viability, with the strongest effects seen at 25 µM. Among them, compound 70 showed the most significant antiproliferative activity, while compounds KCO69 and KCO129 exhibited moderate effects. Variability in treatment response among cultures reflected the inherent heterogeneity of patient-derived tumors. Overall, establishing primary brain cancer cell models from Saudi patients offers a valuable platform for preclinical drug screening and supports further research on these compounds as potential therapies for brain cancer.
- 9 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7139
Open AccessSaudi Patient-Derived Brain and Intracranial Explanted Tumor Cells: Isolation, Growth, and Anticancer Drug Screening
Brain cancer is a highly aggressive disease with limited treatment options, highlighting the need for reliable preclinical models for drug discovery. This study aimed to isolate and characterize Saudi patient-derived primary brain cancer cells and assess the anticancer activity of novel compounds developed in-house. Sixteen tumor samples from Saudi patients were processed to establish primary brain cancer cultures and One Normal Tissue (Control). The cells were successfully isolated and maintained under optimized conditions, with their morphology and growth characteristics monitored. Molecular analysis confirmed the expression of key tumor and neural markers. The anticancer activity of selected compounds, KCO69, KCO70, and KCO129, was tested at various concentrations using the MTT and CellTiter-Glo Luminescent Cell Viability Assay. All compounds caused a concentration-dependent reduction in cell viability, with the strongest effects seen at 25 µM. Among them, compound 70 showed the most significant antiproliferative activity, while compounds KCO69 and KCO129 exhibited moderate effects. Variability in treatment response among cultures reflected the inherent heterogeneity of patient-derived tumors. Overall, establishing primary brain cancer cell models from Saudi patients offers a valuable platform for preclinical drug screening and supports further research on these compounds as potential therapies for brain cancer.
- Open Access
- 29 April 2026
- Published by MDPI AG in Preprints.org
Isolation, Growth, and Characterization of Saudi Explanted Primary Brain Cancer Cells for Drug Discovery Purposes
Brain cancer is a highly aggressive disease with limited treatment options, highlighting the need for reliable preclinical models for drug discovery. This study aimed to isolate and characterize Saudi patient–derived primary brain cancer cells and assess the anticancer activity of novel compounds developed in-house. Sixteen tumor samples from Saudi patients were processed to establish primary brain cancer cultures and One Normal Tissue (Control). The cells were successfully isolated and maintained under optimized conditions, with their morphology and growth characteristics monitored. Molecular analysis confirmed the expression of key tumor and neural markers. The anticancer activity of selected compounds KCO69, KCO70, and KCO129 was tested at various concentrations using the MTT and CellTiter-Glo Luminescent Cell Viability Assay. All compounds caused a concentration-dependent reduction in cell viability, with the strongest effects seen at 25 µM. Among them, compound 70 showed the most significant antiproliferative activity, while compounds KCO69 and KCO129 exhibited moderate effects. Variability in treatment response among cultures reflected the inherent heterogeneity of patient-derived tumors. Overall, establishing primary brain cancer cell models from Saudi patients offers a valuable platform for preclinical drug screening and supports further research on these compounds as potential therapies for brain cancer.
- 29 April 2026
- Published by MDPI AG in Preprints.org
Open AccessIsolation, Growth, and Characterization of Saudi Explanted Primary Brain Cancer Cells for Drug Discovery Purposes
Brain cancer is a highly aggressive disease with limited treatment options, highlighting the need for reliable preclinical models for drug discovery. This study aimed to isolate and characterize Saudi patient–derived primary brain cancer cells and assess the anticancer activity of novel compounds developed in-house. Sixteen tumor samples from Saudi patients were processed to establish primary brain cancer cultures and One Normal Tissue (Control). The cells were successfully isolated and maintained under optimized conditions, with their morphology and growth characteristics monitored. Molecular analysis confirmed the expression of key tumor and neural markers. The anticancer activity of selected compounds KCO69, KCO70, and KCO129 was tested at various concentrations using the MTT and CellTiter-Glo Luminescent Cell Viability Assay. All compounds caused a concentration-dependent reduction in cell viability, with the strongest effects seen at 25 µM. Among them, compound 70 showed the most significant antiproliferative activity, while compounds KCO69 and KCO129 exhibited moderate effects. Variability in treatment response among cultures reflected the inherent heterogeneity of patient-derived tumors. Overall, establishing primary brain cancer cell models from Saudi patients offers a valuable platform for preclinical drug screening and supports further research on these compounds as potential therapies for brain cancer.
- Open Access
- 25 July 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 300
Polymorphous low-grade neuroepithelial tumor of the young
Background: Polymorphous low-grade neuroepithelial tumor of the young (PLNTY) is a newly recognized entity first described in 2017. This article reports the clinical, radiological, histological, and molecular characteristics of PLNTY diagnosed in a young female. Case Description: A 20-year-old female, not known to have any medical illness, presented to the emergency department with speech arrest that progressed to generalized tonic-clonic seizures. Brain magnetic resonance imaging showed a T2 hyperintense nonenhancing cortical-based heterogeneous mass in the left medial temporal lobe and adjacent inferior temporal gyrus measuring 2.7 × 2 × 2.5 cm with no susceptibility signal or diffusion restriction. Electroencephalogram (EEG) showed left temporal epileptiform discharges. She underwent left frontotemporal craniotomy and tumor resection. The light microscopic examination of the tumor revealed a low-grade infiltrative neoplasm. There was a classical appearance of round cells with perinuclear halo, immunopositive for olig-2, glial fibrillary acidic protein (GFAP), and cluster of differentiation-34. There was B-Raf protooncogene, serine/threonine kinase (BRAF) c.1799T>A (p.V600E) point mutation and absence of isocitrate dehydrogenase (IDH) 1 and 2 hotspot mutations. The overall findings were diagnostic of PLNTY. Conclusion: This article reports an additional case of PLNTY, a newly defined central nervous system tumor entity, describing its clinical, radiological, histological, and molecular features.
- 25 July 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 300
Open AccessPolymorphous low-grade neuroepithelial tumor of the young
Background: Polymorphous low-grade neuroepithelial tumor of the young (PLNTY) is a newly recognized entity first described in 2017. This article reports the clinical, radiological, histological, and molecular characteristics of PLNTY diagnosed in a young female. Case Description: A 20-year-old female, not known to have any medical illness, presented to the emergency department with speech arrest that progressed to generalized tonic-clonic seizures. Brain magnetic resonance imaging showed a T2 hyperintense nonenhancing cortical-based heterogeneous mass in the left medial temporal lobe and adjacent inferior temporal gyrus measuring 2.7 × 2 × 2.5 cm with no susceptibility signal or diffusion restriction. Electroencephalogram (EEG) showed left temporal epileptiform discharges. She underwent left frontotemporal craniotomy and tumor resection. The light microscopic examination of the tumor revealed a low-grade infiltrative neoplasm. There was a classical appearance of round cells with perinuclear halo, immunopositive for olig-2, glial fibrillary acidic protein (GFAP), and cluster of differentiation-34. There was B-Raf protooncogene, serine/threonine kinase (BRAF) c.1799T>A (p.V600E) point mutation and absence of isocitrate dehydrogenase (IDH) 1 and 2 hotspot mutations. The overall findings were diagnostic of PLNTY. Conclusion: This article reports an additional case of PLNTY, a newly defined central nervous system tumor entity, describing its clinical, radiological, histological, and molecular features.
- Open Access
- 1 April 2024
- Published by Armed Forces Medical Services in Neurosciences
- Vol. 29 (2) , 139-143
Sporadic subependymal giant cell astrocytoma with somatic TSC2 mutation: A case report
Subependymal giant cell astrocytoma (SEGA) is a rare circumscribed astrocytic glioma that occurs in approximately 25% of all tuberous sclerosis (TSC) cases. Herein, we discuss an atypical presentation of SEGA, including the genetic alterations, impact on clinical presentation, and the determinants of each medical and surgical treatment option. A 14-year-old girl presented with intermittent headache and a right intraventricular mass originating near the foramen of Monro. The tumor’s proximity to critical structures necessitated maximum safe resection, which improved her symptoms. Histological findings indicated SEGA, and genetic sequencing revealed a TSC2 mutation. However, complete clinical and radiological evaluations failed to reveal TSC. Two months later, a new subependymal nodule was incidentally found. She had a recurrent left occipital horn lesion and diffuse smooth leptomeningeal enhancement with no spine drop metastases. She was administered everolimus as the tumor was considered unresectable. Subsequent imaging revealed a reduction in both residual and new lesions.
- 1 April 2024
- Published by Armed Forces Medical Services in Neurosciences
- Vol. 29 (2) , 139-143
Open AccessSporadic subependymal giant cell astrocytoma with somatic TSC2 mutation: A case report
Subependymal giant cell astrocytoma (SEGA) is a rare circumscribed astrocytic glioma that occurs in approximately 25% of all tuberous sclerosis (TSC) cases. Herein, we discuss an atypical presentation of SEGA, including the genetic alterations, impact on clinical presentation, and the determinants of each medical and surgical treatment option. A 14-year-old girl presented with intermittent headache and a right intraventricular mass originating near the foramen of Monro. The tumor’s proximity to critical structures necessitated maximum safe resection, which improved her symptoms. Histological findings indicated SEGA, and genetic sequencing revealed a TSC2 mutation. However, complete clinical and radiological evaluations failed to reveal TSC. Two months later, a new subependymal nodule was incidentally found. She had a recurrent left occipital horn lesion and diffuse smooth leptomeningeal enhancement with no spine drop metastases. She was administered everolimus as the tumor was considered unresectable. Subsequent imaging revealed a reduction in both residual and new lesions.
- Open Access
- 1 May 2023
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 106, 108133
Juvenile ossifying fibroma in anterior ethmoidal sinus in B-cell acute lymphoblastic leukemia and MHC class II deficiency patient: Case report
Juvenile ossifying fibromas (JOF) are rare benign tumors affecting the craniofacial area, and they present more in younger age groups. JOFs are aggressive lesions and have a high tendency for recurring after surgical resection. A 9-years-old female who was a known case of major histocompatibility complex class II deficiency since birth and post hematopoietic stem cell transplant was diagnosed with B-cell acute lymphoblastic leukemia (ALL). Right anterior ethmoidal sinus opacification with mucosal thickening found on sinus imaging was initially thought to be infectious in origin due to the patient's immunodeficiency. However, further investigation and endoscopic sinus surgery with lesion debridement and biopsy revealed psammomatoid JOF. Follow up and imaging results urged the need for a second surgery, but no recurrence was detected. As the patient's ALL was being treated, the case was followed up for two months with imaging showing opacification in multiple sinuses which was suspected to be fungal infection due to immunodeficiency. The complicated character of the case may have hindered any additional invasive management. Opacification persisted despite conservative management. Unfortunately, the patient suffered from disease complication, infections, and died from multi-organ failure. This case highlights the importance of a thorough diagnostic workup and management strategy for immunodeficient patients with JOF. JOF's recurrent nature along with the pre-existing immunodeficiency made this case difficult to manage as the patient had other life-threatening condition. Specific management considerations should take place in immunocompromised patients. Post-operative long-term follow-ups are needed for early detection of recurrence.
- 1 May 2023
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 106, 108133
Open AccessJuvenile ossifying fibroma in anterior ethmoidal sinus in B-cell acute lymphoblastic leukemia and MHC class II deficiency patient: Case report
Juvenile ossifying fibromas (JOF) are rare benign tumors affecting the craniofacial area, and they present more in younger age groups. JOFs are aggressive lesions and have a high tendency for recurring after surgical resection. A 9-years-old female who was a known case of major histocompatibility complex class II deficiency since birth and post hematopoietic stem cell transplant was diagnosed with B-cell acute lymphoblastic leukemia (ALL). Right anterior ethmoidal sinus opacification with mucosal thickening found on sinus imaging was initially thought to be infectious in origin due to the patient's immunodeficiency. However, further investigation and endoscopic sinus surgery with lesion debridement and biopsy revealed psammomatoid JOF. Follow up and imaging results urged the need for a second surgery, but no recurrence was detected. As the patient's ALL was being treated, the case was followed up for two months with imaging showing opacification in multiple sinuses which was suspected to be fungal infection due to immunodeficiency. The complicated character of the case may have hindered any additional invasive management. Opacification persisted despite conservative management. Unfortunately, the patient suffered from disease complication, infections, and died from multi-organ failure. This case highlights the importance of a thorough diagnostic workup and management strategy for immunodeficient patients with JOF. JOF's recurrent nature along with the pre-existing immunodeficiency made this case difficult to manage as the patient had other life-threatening condition. Specific management considerations should take place in immunocompromised patients. Post-operative long-term follow-ups are needed for early detection of recurrence.
- Open Access
- 22 April 2022
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 13, 160
Primary spinal cord glioblastoma: A rare cause of paraplegia
Background: Primary spinal glioblastomas are extremely rare neoplasms and account for only 0.2% of glioblastoma cases. Due to the rare incidence of spinal cord glioblastoma in the literature, its natural history/ outcome remains undetermined. The present article describes the clinical presentation, radiological/pathological characteristics, and outcome of the primary spinal cord glioblastoma.Case Description: Two young patients initially presented with paresis that rapidly progressed to paraplegia. Nondermatomal sensory deficits were also noted, mainly affecting the lower limbs. Neuroradiological imaging revealed an extensive intramedullary spinal cord lesion, with no evidence of concurrent intracranial space-occupying lesions. Thoracic laminectomy, followed by tumor debulking and/or biopsy, was performed. The histomorphology was suggestive of glioblastoma, the World Health Organization grade 4 (Isocitrate Dehydrogenase-wild type). They were discharged in stable condition and were started on chemoradiotherapy, with clinicoradiological follow-up. One patient passed away after 9 months of initial presentation. The other patient was alive at 6-month follow-up.Conclusion: Primary spinal glioblastoma is a rare and challenging tumor. Patients commonly present with a progressive paresis, resulting in paraplegia, regardless of the surgical resection extent, and received adjuvant chemotherapy. Therefore, primary spinal cord glioblastoma should be considered in patients reporting a rapid lower limb weakness with neuroradiological evidence of extensive, exophytic intramedullary lesion of the spine. A biopsy-proven histopathological diagnosis is of indisputable importance to establish the final diagnosis and plan treatment options.
- 22 April 2022
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 13, 160
Open AccessPrimary spinal cord glioblastoma: A rare cause of paraplegia
Background: Primary spinal glioblastomas are extremely rare neoplasms and account for only 0.2% of glioblastoma cases. Due to the rare incidence of spinal cord glioblastoma in the literature, its natural history/ outcome remains undetermined. The present article describes the clinical presentation, radiological/pathological characteristics, and outcome of the primary spinal cord glioblastoma.Case Description: Two young patients initially presented with paresis that rapidly progressed to paraplegia. Nondermatomal sensory deficits were also noted, mainly affecting the lower limbs. Neuroradiological imaging revealed an extensive intramedullary spinal cord lesion, with no evidence of concurrent intracranial space-occupying lesions. Thoracic laminectomy, followed by tumor debulking and/or biopsy, was performed. The histomorphology was suggestive of glioblastoma, the World Health Organization grade 4 (Isocitrate Dehydrogenase-wild type). They were discharged in stable condition and were started on chemoradiotherapy, with clinicoradiological follow-up. One patient passed away after 9 months of initial presentation. The other patient was alive at 6-month follow-up.Conclusion: Primary spinal glioblastoma is a rare and challenging tumor. Patients commonly present with a progressive paresis, resulting in paraplegia, regardless of the surgical resection extent, and received adjuvant chemotherapy. Therefore, primary spinal cord glioblastoma should be considered in patients reporting a rapid lower limb weakness with neuroradiological evidence of extensive, exophytic intramedullary lesion of the spine. A biopsy-proven histopathological diagnosis is of indisputable importance to establish the final diagnosis and plan treatment options.
- Open Access
- 25 March 2022
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 13, 109
Metastatic brain lesion as the initial presentation of follicular thyroid carcinoma
Background: Metastatic brain lesions, of thyroid origin, are rare manifestations of differentiated thyroid cancer, with papillary thyroid carcinoma being the most common subtype. Considering the rarity of metastatic follicular thyroid carcinoma to the brain, the present article outlines its clinical presentation, neuroradiological findings, pathological features, and outcome. Case Description: A 52-year-old female presented with a 6-month history of progressive and holocephalic headache. Examination revealed a tracheal deviation to the left side due to an enlarged goiter. Brain CT scan showed a right occipital, slightly hyperdense lesion associated with a 0.4 cm midline shift to the left side. Brain MRI demonstrated a right occipital, avidly-enhancing, extra-axial lesion with disproportionate and extensive vasogenic edema. As the lesion was solitary, the patient underwent craniotomy and tumor resection. Histopathological examination revealed a tumor consistent of small follicles, composed of uniform round nuclei without papillary thyroid carcinoma nuclear features, suggestive of metastatic follicular thyroid carcinoma to the brain. Postoperatively, the patient was neurologically intact. She was discharged in a stable condition with laboratory/ radiological investigations and follow-up at neurosurgery, endocrine, radiotherapy, and thyroid surgery clinics. Conclusion: Follicular thyroid carcinoma may rarely metastasize to the central nervous system. A high index of suspicion is required to identify patients with thyroid cancer who initially present with neurological manifestations. Complete surgical resection of the metastatic brain lesion is safe, feasible and is associated with a prolonged overall survival.
- 25 March 2022
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 13, 109
Open AccessMetastatic brain lesion as the initial presentation of follicular thyroid carcinoma
Background: Metastatic brain lesions, of thyroid origin, are rare manifestations of differentiated thyroid cancer, with papillary thyroid carcinoma being the most common subtype. Considering the rarity of metastatic follicular thyroid carcinoma to the brain, the present article outlines its clinical presentation, neuroradiological findings, pathological features, and outcome. Case Description: A 52-year-old female presented with a 6-month history of progressive and holocephalic headache. Examination revealed a tracheal deviation to the left side due to an enlarged goiter. Brain CT scan showed a right occipital, slightly hyperdense lesion associated with a 0.4 cm midline shift to the left side. Brain MRI demonstrated a right occipital, avidly-enhancing, extra-axial lesion with disproportionate and extensive vasogenic edema. As the lesion was solitary, the patient underwent craniotomy and tumor resection. Histopathological examination revealed a tumor consistent of small follicles, composed of uniform round nuclei without papillary thyroid carcinoma nuclear features, suggestive of metastatic follicular thyroid carcinoma to the brain. Postoperatively, the patient was neurologically intact. She was discharged in a stable condition with laboratory/ radiological investigations and follow-up at neurosurgery, endocrine, radiotherapy, and thyroid surgery clinics. Conclusion: Follicular thyroid carcinoma may rarely metastasize to the central nervous system. A high index of suspicion is required to identify patients with thyroid cancer who initially present with neurological manifestations. Complete surgical resection of the metastatic brain lesion is safe, feasible and is associated with a prolonged overall survival.
- 1 May 2021
- Published by Elsevier in World Neurosurgery
- Vol. 149, e298-e308
Endoscopic versus Open Microsurgical Excision of Colloid Cysts: A Comparative Analysis and State-of-the-Art Review of Neurosurgical Techniques
- 1 May 2021
- Published by Elsevier in World Neurosurgery
- Vol. 149, e298-e308
Endoscopic versus Open Microsurgical Excision of Colloid Cysts: A Comparative Analysis and State-of-the-Art Review of Neurosurgical Techniques
- Open Access
- 1 July 2020
- Published by Armed Forces Medical Services in Neurosciences
- Vol. 25 (3) , 218-221
Spectrum of medulloblastoma subtypes and frequency of MYC amplification; Experience from a tertiary care center in Saudi Arabia
To clarify the spectrum of morphological and molecular subtypes of medulloblastoma (MBL), in addition to MYC and MYCN amplification statuses in a cohort of Saudi patients. The latter was correlated with patient outcome. We conducted a retrospective cohort study of 57 patients with MBL, diagnosed at the central laboratory of King Abdulaziz Medical City in Riyadh, Saudi Arabia, between 2006 and 2019. Molecular analysis for MYC and MYCN amplification was performed for the 19 most recently diagnosed patients. Classic MBL was the most prevalent histologic subtype and MBL with extensive nodularity was the rarest. The non-WNT/non-SHH molecular subgroup was the most common while the WNT-activated was the least common. Among 19 patients analyzed, MYC and MYCN amplifications were discovered in 2 (10.5%) and 1 (5.3%) cases, respectively, using interphase fluorescence in-situ hybridization. The 2 MYC amplified cases belonged to the large cell/anaplastic subtype and had the worst outcomes. The MYC amplification corresponded with poor prognosis, the large cell/anaplastic variant of MBL, and the non-WNT/non-SHH molecular subtype.
- 1 July 2020
- Published by Armed Forces Medical Services in Neurosciences
- Vol. 25 (3) , 218-221
Open AccessSpectrum of medulloblastoma subtypes and frequency of MYC amplification; Experience from a tertiary care center in Saudi Arabia
To clarify the spectrum of morphological and molecular subtypes of medulloblastoma (MBL), in addition to MYC and MYCN amplification statuses in a cohort of Saudi patients. The latter was correlated with patient outcome. We conducted a retrospective cohort study of 57 patients with MBL, diagnosed at the central laboratory of King Abdulaziz Medical City in Riyadh, Saudi Arabia, between 2006 and 2019. Molecular analysis for MYC and MYCN amplification was performed for the 19 most recently diagnosed patients. Classic MBL was the most prevalent histologic subtype and MBL with extensive nodularity was the rarest. The non-WNT/non-SHH molecular subgroup was the most common while the WNT-activated was the least common. Among 19 patients analyzed, MYC and MYCN amplifications were discovered in 2 (10.5%) and 1 (5.3%) cases, respectively, using interphase fluorescence in-situ hybridization. The 2 MYC amplified cases belonged to the large cell/anaplastic subtype and had the worst outcomes. The MYC amplification corresponded with poor prognosis, the large cell/anaplastic variant of MBL, and the non-WNT/non-SHH molecular subtype.